Here's what we'll cover Here's what we'll cover Here's what we'll cover For too long, people with obesity have been stigmatized, misled about the most effective ways to improve their health, and unable to get the care and support they need
Target-based drug discovery: is something wrong
As pharmaceutical companies invest in research and development, the introduction of novel agents could reshape treatment paradigms, offering new hope for individuals struggling with metabolic disorders

Efficacy Mean weight loss rate Percentage of patients achieving 20%, 25%, and 30% or more weight loss Effects in diabetic patients Changes in body fat and lean body mass Weight loss maintenance and weight regain after discontinuation Safety and Tolerability Nausea, vomiting, diarrhea, and constipation Gallbladder and biliary events Pancreatitis Increased heart rate Liver dysfunction Hypoglycemia Discontinuation rate due to adverse events Organ Outcomes Cardiovascular events Renal function Heart failure MASH and liver fibrosis Sleep apnea Joint symptoms Product characteristics Injection or oral Once-weekly or once-monthly Dietary and fluid restrictions Room temperature storage Device Complexity of dose titration Supply and access API and formulation production capacity Supply of pen injectors Drug pricing Insurance reimbursement Access in China, India, South America, etc
Animal-lifespan findings vary by strain and outcome